Potential drug interactions in dermatologic outpatient prescriptions - Experience from nationwide population-based study in Taiwan

Dermatologica Sinica

Volumn 29, Issue 3, 2011, Pages 81-85

  Chang, Ying Jui ^a,b   Yeh, Min Li ^a,c   Li, Yu Chuan ^d,e   Hsu, Chien Yeh ^e   Yen, Yung Tai ^e   Wang, Po Yen ^e   Chu, Thomas Waitao ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adverse drug reactions; Dermatologic prescriptions; Drug interactions; Information technology; National Health Insurance; Patient safety

Indexed keywords

ALUMINUM HYDROXIDE; AMPICILLIN; ANTACID AGENT; ASTEMIZOLE; BETAMETHASONE; CIMETIDINE; CORTICOSTEROID; DEXAMETHASONE; DOXYCYCLINE; ERYTHROMYCIN; FUROSEMIDE; GENTAMICIN; KETOCONAZOLE; MINOCYCLINE; OXACILLIN; PHOSPHATE; RIFAMPICIN; TERFENADINE; TETRACYCLINE; TRIAMCINOLONE;

ARTICLE; DATA BASE; DERMATOLOGY; DRUG INTERACTION; HUMAN; NATIONAL HEALTH INSURANCE; OUTPATIENT; PRESCRIPTION; TAIWAN;

EID: 80053283838     PISSN: 10278117     EISSN: 2223330X     Source Type: Journal    
DOI: 10.1016/j.dsi.2011.07.001     Document Type: Article

References (30)

1. J. Lazarou, B.H. Pomeranz, and P.N. Corey Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1998 1200 1205 (Pubitemid 28193431)
2. L.T. Kohn, J. Corrigan, and M.S. Donaldson To err is human: building a safer health system 2000 National Academy Press Washington, DC
3. Great Britain. Dept. of Health An organisation with a memory: report of an expert group on learning from adverse events in the NHS 2000 Stationery Office London
4. D.W. Bates, D.J. Cullen, and N. Laird Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group JAMA 274 1995 29 34
5. L. Guedon-Moreau, D. Ducrocq, and M.F. Duc Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999 Eur J Clin Pharmacol 59 2003 689 695 (Pubitemid 37494540)
6. D.C. Classen, S.L. Pestotnik, R.S. Evans, J.F. Lloyd, and J.P. Burke Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality JAMA 277 1997 301 306 (Pubitemid 27045010)
7. L.L. Leape, T.A. Brennan, and N. Laird The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II N Engl J Med 324 1991 377 384
8. T.A. Brennan, L.L. Leape, and N.M. Laird Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I N Engl J Med 324 1991 370 376
9. T.K. Gandhi, S.N. Weingart, and J. Borus Adverse drug events in ambulatory care N Engl J Med 348 2003 1556 1564 (Pubitemid 36437933)
10. P. Impicciatore, I. Choonara, A. Clarkson, D. Provasi, C. Pandolfini, and M. Bonati Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies Br J Clin Pharmacol 52 2001 77 83 (Pubitemid 32862772)
11. P.A. Glassman, B. Simon, P. Belperio, and A. Lanto Improving recognition of drug interactions: benefits and barriers to using automated drug alerts Med Care 40 2002 1161 1171
12. J.Z. Litt Litt's drug eruption reference manual including drug interactions 2004 Taylor & Francis London and New York
13. J.C. Roujeau, L. Allanore, Y. Liss, and M. Mockenhaupt Severe Cutaneous Adverse Reactions to Drugs (SCAR): definitions, diagnostic criteria, genetic predisposition Dermatol Sinica 27 2009 203 209
14. W.K. Andersen, and D.S. Feingold Adverse drug interactions clinically important for the dermatologist Arch Dermatol 131 1995 468 473
15. V.P. Barranco Clinically significant drug interactions in dermatology J Am Acad Dermatol 38 1998 599 612 (Pubitemid 28182932)
16. V.P. Barranco Update on clinically significant drug interactions in dermatology J Am Acad Dermatol 51 2004 E4
17. V.P. Barranco Update on clinically significant drug interactions in dermatology J Am Acad Dermatol 54 2006 676 684
18. Program overview of national health insurance Available from: Nov. 17, 2009 http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&;menu-id= 590&webdata-id=3189&WD-ID=590 Accessed April 29, 2011
19. Y.L. Huang, Y.J. Chen, and M.W. Lin Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study Br J Dermatol 161 2009 854 860
20. D.D. Lee, C.K. Huang, P.C. Ko, Y.T. Chang, W.Z. Sun, and Y.J. Oyang Association of primary cutaneous amyloidosis with atopic dermatitis: a nationwide population-based study in Taiwan Br J Dermatol 164 2011 148 153
21. D.S. Tatro Drug interaction facts 2001 2001 Facts & Comparisons St Louis, MO
22. D.S. Tatro Significance rating Drug interaction facts 2001 2001 Facts & Comparisons St Louis, MO p. xiv-xv
23. J.A. Yagiela Adverse drug interactions in dental practice: interactions associated with vasoconstrictors: part V of a series J Am Dental Assoc 130 1999 701 709
24. D.S. Tatro Corticosteroid and antacids Drug interaction facts 2001 2001 Facts & Comparisons St Louis, MO p. 367
25. J.Q. Del Rosso Oral antibiotic drug interactions of clinical significance to dermatologists Dermatol Clin 27 2009 91 94
26. K.W. Davidson, A. Kahn, and R.D. Price Reduction of adverse drug reactions by computerized drug interaction screening J Fam Pract 25 1987 371 375 (Pubitemid 18010179)
27. H.J. Murff, V.L. Patel, G. Hripcsak, and D.W. Bates Detecting adverse events for patient safety research: a review of current methodologies J Biomed Inform 36 2003 131 143 (Pubitemid 37209987)
28. D.W. Bates, and A.A. Gawande Improving safety with information technology N Engl J Med 348 2003 2526 2534 (Pubitemid 36706541)
29. J.P. Callen Complications and adverse reactions in the use of newer biologic agents Semin Cutan Med Surg 26 2007 6 14 (Pubitemid 46349778)
30. H.L. Tey, E.L. Tian, and A.W. Tan Drug interactions in dermatological practice Clin Exp Dermatol 33 2008 541 550